Saturday 7 November 2026 Export ATNM’s income statement to Excel — free account

Actinium Pharmaceuticals, Inc.

Actinium Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $90,000.00, up 11.1% from fiscal 2023.

Revenue: +77,677.8%
EPS: +504.6%
Free cash flow: −4.91%

Quarter to June 2026, against a year earlier

1.42 0.12 +9.23%

Follow ATNM

Alert me

Market cap: $40.9M
P/E: 3.9×
Fwd P/E: 8.4×
Dividend yield: —
F-score: n/a
Altman Z: −11.85
Beneish M: n/a
Dividend safety: n/a

Overview

Insider Decisions last twelve months

Trades a month
	Jan 26			Apr 26			Jul 26			Oct 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 1.62%

Capital & Financial Ratios $m

Size

Market Cap 40.87

Revenue ttm 35.14

Net income ttm 11.31

Free cash flow ttm (23.25)

Net debt Q (36.47)

Valuation

P/E 3.94

Forward P/E 8.38

Price / sales 1.27

Forward P/S Powerpack

Price / FCF 0.00

Price / book 1.47

Financial health

Current ratio Q 4.08

Debt / equity Q 0.00

Interest coverage Q (13.35)

Growth

Revenue growth Q +77,677.78%

Operating income growth Q +467.39%

EPS, this year +116.21%

EPS, next year A −420.75%

Revenue, next year A +38,788.89%

EPS, past 5 yrs —

EPS, next 5 yrs A +20.23%

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 7.14%

10-year low 10-year high

P/B against its own 10 years 10.70%

10-year low 10-year high

Dividends

Yield: —
Annual rate: —
Payout ratio: —

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	77	73	48	36
Receivables	—	—	—	—
Inventory	—	—	—	—
Other	—	—	—	—
	78	75	49	38

	2023	2024	2025	Q'26
Payables	8	8	7	9
ST’ Debt	—	—	—	—
Other	—	—	—	—
	8	8	8	9

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	(57.15%)
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	(9.80%)	(33.74%)	(50.97%)

Earnings Trends EPS, adjusted, against the consensus

Q2 FY26 Estimate −0.20 Actual 0.89

−0.42 −0.05 0.32 0.69 1.06

Q3 FY25 Beat +0.09

Q4 FY25 Beat +0.01

Q1 FY26 Beat +0.04

Q2 FY26 Beat +1.09

Q3 FY26 — Nov 13

Earnings per share against the consensus, by quarter
Quarter	Estimate	Reported	Result
Q3 FY25	−0.25	−0.16	Beat by 0.09
Q4 FY25	−0.20	−0.19	Beat by 0.01
Q1 FY26	−0.22	−0.18	Beat by 0.04
Q2 FY26	−0.20	0.89	Beat by 1.09
Q3 FY26	−0.25	—	Reports 13 November 2026

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.18)	0.89	—	—	—
’25	(0.51)	(0.22)	(0.16)	(0.19)	(1.09)
’24	(0.31)	(0.38)	(0.37)	(0.21)	(1.27)
’23	(0.43)	(0.58)	(0.49)	(0.33)	(1.83)
’22	(0.23)	(0.33)	(0.38)	(0.42)	(1.37)
’21	(0.29)	(0.25)	(0.30)	(0.37)	(1.20)
’20	(0.98)	(0.41)	(0.36)	(0.09)	(1.83)

Fiscal quarters ending in the months shown.

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	—	35	—	—	—
’25	—	—	0	—	0
’23	—	—	—	—	0
’22	1	0	0	0	1

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(6)	(5)	—	—	—
’25	(8)	(5)	(6)	(5)	(25)
’24	(7)	(8)	(12)	(6)	(33)
’23	(15)	(14)	(11)	(7)	(47)
’22	(6)	28	(6)	(8)	9
’21	(6)	(5)	(6)	(5)	(21)
’20	(6)	(5)	(5)	(6)	(22)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(6)	(6)	—	—	—
’25	(8)	(5)	(6)	(5)	(25)
’24	(7)	(8)	(12)	(6)	(33)
’23	(15)	(14)	(11)	(7)	(47)
’22	(6)	28	(6)	(8)	8
’21	(6)	(5)	(6)	(5)	(21)
’20	(6)	(5)	(5)	(7)	(22)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	TTM Jun ’26	Trend	10 yrs	2026e	2027e	2028e	Next 3/yr
													Ten-year view		Analyst estimates Powerpack
Income, $m
Income, $m	Revenue	—	—	—	—	—	1	1	0	—	0	35		(47.0%)	35	35	17	+478.9%
	Gross margin, %	0.00	0.00	0.00	0.00	0.00	100.00	100.00	100.00	—	100.00	98.71		+100.0 pt	Powerpack Actinium Pharmaceuticals, Inc.’s next three years, line by line Analysts expect revenue to grow 478.9% a year to 2028 — faster than the −47.0% of the last 4 years. See the consensus for every other line: earnings, margins, cash flow, valuation and returns. Unlock estimates Try Powerpack free for 7 days, then $99 / year ($8.25 a month). Cancel any time. Also in Powerpack: every quarter, Excel exports, API & MCP access. Compare plans
	EBT	(24)	(27)	(24)	(22)	(22)	(25)	(33)	(49)	(38)	(34)	11		+3.8%
	EBT margin, %	0.00	0.00	0.00	0.00	0.00	(2,165.56)	(3,205.53)	(60,269.14)	0.00	(37,652.22)	32.18		(37,652.2) pt
	Net income	(24)	(27)	(24)	(22)	(22)	(25)	(33)	(49)	(38)	(34)	11		+3.8%
Per share, $
Per share, $	Revenue	0.00	0.00	0.00	0.00	0.00	0.06	0.04	0.00	0.00	0.00	1.12		n/m
	Earnings	(15.01)	(12.01)	(6.61)	(4.33)	(1.83)	(1.17)	(1.37)	(1.83)	(1.27)	(1.09)	0.36		(25.3%)
	Cash flow	(12.88)	(9.70)	(5.83)	(4.31)	(1.78)	(1.01)	0.36	(1.78)	(1.10)	(0.79)	(0.72)		(26.7%)
	Capex	(0.04)	(0.01)	(0.03)	(0.01)	(0.02)	(0.01)	(0.02)	(0.01)	0.00	0.00	(0.02)		(23.6%)
	Free cash flow	(12.92)	(9.71)	(5.85)	(4.33)	(1.80)	(1.02)	0.34	(1.78)	(1.10)	(0.79)	(0.74)		(26.7%)
	Book value	11.16	6.15	2.50	1.13	5.05	3.58	2.75	1.37	1.09	0.25	0.97		(34.4%)
	Shares, m	2	2	4	5	12	21	24	27	30	31	31		+39.0%
Valuation, ×
Valuation, ×	P/E	—	—	—	—	—	0.00	0.00	0.00	—	0.00	3.94		0.0
	P/S	—	—	—	—	—	108.06	234.86	137.41	—	235.70	1.27		179.0
	P/B	—	—	—	—	—	1.68	3.64	3.89	—	5.42	1.47		3.7
	EV/Sales	—	—	—	—	—	39.64	130.76	62.99	—	(30.94)	0.23		50.6
	EV/FCF	—	—	—	—	—	(2.16)	16.27	(1.37)	—	0.23	(0.35)		3.2
Cash, $m
Cash, $m	Operating cash flow	(21)	(22)	(21)	(21)	(22)	(21)	9	(47)	(33)	(25)	(23)		+1.9%
	Capex	0	0	0	0	0	0	0	0	0	0	(1)		+6.3%
	Free cash flow	(21)	(22)	(21)	(22)	(22)	(21)	8	(47)	(33)	(25)	(23)		+1.9%
Balance, $m
Balance, $m	Working capital	18	13	8	5	60	73	100	70	66	41	28		+9.8%
	Net debt	(21)	(17)	(14)	(9)	(64)	(78)	(107)	(77)	(73)	(48)	(36)		+9.9%
	Shareholders’ equity	18	14	9	6	61	74	66	36	33	8	30		(8.8%)
Returns, %
Returns, %	ROA	(99.04)	(130.19)	(142.38)	(164.92)	(56.92)	(33.76)	(33.94)	(49.91)	(48.30)	(52.67)	21.92		+46.4 pt
	ROIC	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		0.0 pt
	ROE	(121.66)	(167.94)	(210.41)	(302.99)	(66.35)	(36.74)	(47.16)	(94.92)	(110.63)	(166.96)	45.86		(45.3) pt
People
People	Employees	23	25	30	25	32	32	49	49	37	25	—		+0.9%
	Revenue/emp, $m	0.00	0.00	0.00	0.00	0.00	0.04	0.02	0.00	0.00	0.00	—		n/m

Negative figures in brackets.

estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
BMEA Biomea Fusion, Inc.	$42.6M	— (loss-making)	—	—	n/m	+47.80% (above 0%: growing)	0.00%	0.00%	Compare
ATHE Alterity Therapeutics Limited - Sponsored ADR	$42.4M	— (loss-making)	—	—	0.00%	−84.83% (below 0%: shrinking)	0.00%	—	Compare
GANX Gain Therapeutics, Inc.	$41.9M	— (loss-making)	— (loss-making)	+27.78% (above 0%: growing)	n/m	+8.22% (above 0%: growing)	0.00%	0.00%	Compare
SER Serina Therapeutics, Inc.	$41.9M	— (loss-making)	— (loss-making)	+2,500.00% (above 0%: growing)	n/m	−76.82% (below 0%: shrinking)	100.00%	0.00%	Compare
SGMOQ Sangamo Therapeutics, Inc.	$41.9M	— (loss-making)	— (loss-making)	−77.60% (below 0%: shrinking)	n/m	+26.21% (above 0%: growing)	100.00%	(2,215.40%)	Compare
LONA LeonaBio, Inc.	$40.9M	— (loss-making)	—	—	n/m	−142.29% (below 0%: shrinking)	0.00%	0.00%	Compare
ATNM Actinium Pharmaceuticals, Inc.	$40.9M	3.9×	8.4×	+77,677.78% (above 0%: growing)	n/m	−4.91% (below 0%: shrinking)	100.00%	78.76%
HYPD Hyperion DeFi, Inc.	$39.8M	— (loss-making)	0.5×	+2,333.33% (above 0%: growing)	n/m	+86.82% (above 0%: growing)	100.00%	8,668.63%	Compare
DWTX Dogwood Therapeutics, Inc	$39.8M	— (loss-making)	—	—	n/m	+10.31% (above 0%: growing)	—	0.00%	Compare
Median of peers	$41.9M	—	—	+1,180.56%	—	+9.27%	0.00%	0.00%

All 621 Biotechnology stocks →

Pay and ownership Proxy statement filed 15 October 2026

Chief executive’s pay

Year	Total pay	Actually paid	$100 invested
2025	1.19m	(658.33k)	47.70
2024	1.17m	(4.50m)	11.83
2023	4.70m	(1.13m)	12.77

Ownership

Directors and executive officers, together less than 1%

Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s shares at the start of the earliest year shown was worth at each year’s end. Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Actinium Pharmaceuticals, Inc. (ATNM) Latest News

23 Oct

Impact 4 · 8:00 AM · PR Newswire

Actinium Pharmaceuticals to Highlight First-in-Human Phase 1 Study of ATNM-400 a HER3-Targeted Non-PSMA Radiotherapy in Prostate Cancer at ESMO 2026

20 Oct

Impact 4 · 8:00 AM · PR Newswire

Actinium Pharmaceuticals Unveils ATNM‑400 Data at EANM 2026 with a First‑In‑Human HER3‑Targeted Radiotherapy Approach Beyond PSMA in Prostate Cancer

Impact 4 · 7:30 AM · PR Newswire

Actinium Pharmaceuticals Presents EANM 2026 Results Reinforcing ATNM-400's Pan-Tumor Potential Across Lung, Colorectal and Ovarian Cancer Models

19 Oct

Impact 4 · 7:30 AM · PR Newswire

Actinium Pharmaceuticals to Showcase ATNM-400's First-in-Human Clinical Data in Prostate Cancer and Preclinical Results in Lung Cancer Supporting Pan-Tumor Potential Today at EANM 2026

16 Oct

Impact 4 · 7:30 AM · PR Newswire

Actinium Pharmaceuticals Appoints Radiopharmaceutical Industry Veteran Sean Maenpaa as Senior Vice President, Business Development

Impact 3 · 8:30 AM · PR Newswire

Actinium Pharmaceuticals Announces Oral and Poster Presentations at EANM 2026 Highlighting Broad Antitumor Activity of ATNM-400 Across Lung, Colorectal and Ovarian Cancer Models

15 Oct

Impact 4 · 8:30 AM · PR Newswire

Actinium Pharmaceuticals Announces Oral Presentation at EANM 2026 Highlighting First-in-Human Phase 1 Study of ATNM-400, a Non-PSMA Targeting Radiotherapy, in Prostate Cancer

Impact 3 · 7:30 AM · PR Newswire

Actinium Pharmaceuticals Strengthens Leadership Team with Appointment of Matt David, M.D. as Chief Financial Officer

15 Sep

Impact 3 · 5:08 AM

ATNM: Initiating Coverage – Diversified Nuclear Medicine Portfolio

14 Aug

Impact 3 · 5:02 PM

Actinium Pharmaceuticals Announces Actimab-A Intellectual Property and Manufacturing Advances and Provides NYSE American Listing Update

3 Jun

Impact 3 · 8:00 AM · PR Newswire

Actinium Presents New ATNM-400 Data in KRAS and EGFR Mutant Models at SNMMI 2026 Supporting a Mutation-Agnostic Opportunity In Non-Small Cell Lung Cancer

Impact 3 · 7:25 AM · PR Newswire

Actinium Pharmaceuticals Oral Presentation at SNMMI 2026 Highlights ATNM-400 Overcoming Resistance to All Three Approved Androgen Receptor Inhibitors and Offers Flexible, Well-Tolerated Dosing in Prostate Cancer Models

1 Jun

Impact 3 · 8:00 AM · PR Newswire

Actinium Appoints Accomplished Oncology Expert Steffen Heeger MD, MSc as Chief Medical Officer to Drive Rejuvenated Pipeline Development

Impact 3 · 7:00 AM · PR Newswire

Actinium Pharmaceuticals Presents New Radiochemistry Data at SNMMI 2026 Demonstrating That CAR Optimization Improves Tumor Targeting and Pharmacokinetics of Actinium-225 Radioconjugates

29 May

Impact 3 · 5:31 PM · PR Newswire

Actinium Pharmaceuticals Receives Two Patent Allowances Spanning Its Actimab-A and Iomab-ACT Programs

6 May

Impact 4 · 8:00 AM · PR Newswire

Actinium Pharmaceuticals Announces Three SNMMI 2026 Presentations Highlighting Differentiated Profile of ATNM-400 Across Lung and Prostate Cancer and Radioconjugate Optimization

22 Apr

Impact 4 · 7:00 AM · PR Newswire

Actinium Pharmaceuticals, Inc. Announces Compelling Pan-Tumor Data for ATNM-400 Demonstrating Broad Efficacy Across Prostate, Lung, and Breast Cancer Models at the 2026 American Association of Cancer Research Annual Meeting

Impact 4 · 7:00 AM · PR Newswire

Actinium Highlights Transcriptional Reprogramming as a Key Mechanism Underpinning Mutation-Agnostic Activity of Actimab-A in AML at the 2026 American Association of Cancer Research Annual Meeting

6 Apr

Impact 3 · 7:30 AM · PR Newswire

Actinium Pharmaceuticals Announces New Pan-Tumor Preclinical Data for ATNM-400 in Solid Tumors and Differentiated Mechanism for Actimab-A in AML to be Presented at 2026 AACR Annual Meeting

22 Dec

Impact 3 · 9:40 AM · Zacks

Are Medical Stocks Lagging Actinium Pharmaceuticals (ATNM) This Year?

12 Dec

Impact 4 · 8:45 AM · PR Newswire

Actinium Pharmaceuticals Presents New Preclinical Data Demonstrating Potent Anti-Tumor Activity of ATNM-400 Across Multiple Breast Cancer Subtypes Including Hormone Receptor-Positive, Triple-Negative, and Tamoxifen- and HER2 Therapy-Resistant Breast Cancer Models at SABCS 2025

1 Dec

Impact 4 · 8:45 AM

Actinium Pharmaceuticals Announces ATNM-400 Data Demonstrating Potent Efficacy in Triple-Negative Breast Cancer and Ability to Overcome Endocrine and HER2-Targeted Therapy Resistance Being Presented at the San Antonio Breast Cancer Symposium

14 Nov

Impact 3 · 5:01 PM · Associated Press Finance

Actinium: Q3 Earnings Snapshot

4 Nov

Impact 4 · 7:30 AM · PR Newswire

Actinium Pharmaceuticals, Inc. to Highlight ATNM-400 Data in Hormone-Resistant and HER2-Resistant Breast Cancer at the 2025 San Antonio Breast Cancer Symposium, Expanding Pan-Tumor Profile Across Three Solid Tumor Indications

3 Nov

Impact 3 · 8:30 AM

Actinium Pharmaceuticals, Inc. to Participate in the Stephens Biotechnology Virtual Fireside Chat Conference

27 Oct

Impact 4 · 7:00 AM · PR Newswire

Actinium Announces Superior Anti-Tumor Activity of ATNM-400 in Lung Cancer Compared to the Leading First, Second and Third-Line Approved EGFR Mutant Therapies and Mechanistic Synergy with Osimertinib at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

24 Oct

Impact 4 · 8:30 AM · PR Newswire

Actinium Pharmaceuticals Presents New Data Demonstrating Potent and Durable Efficacy of ATNM-400, a First-in-Class Multi-Tumor Actinium-225 Radiotherapy, at the 32nd Annual Prostate Cancer Foundation Scientific Retreat

13 Oct

Impact 4 · 12:10 PM · PR Newswire

Actinium Pharmaceuticals to Unveil the Multi-Tumor Potential of ATNM-400, a First-in-Class Actinium-225 Radiotherapy, with Data in Non-Small Cell Lung Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Impact 4 · 8:30 AM · PR Newswire

Actinium to Present ATNM-400 Preclinical Data Highlighting Durable Tumor Control and Ability to Overcome Resistance to Standard-of-Care Prostate Cancer Therapies at the 32nd Annual Prostate Cancer Foundation Scientific Retreat

2 Sep

Impact 4 · 9:40 AM

Is Actinium Pharmaceuticals (ATNM) Stock Outpacing Its Medical Peers This Year?

Insider Decisions last twelve months

Capital & Financial Ratios $m

Valuation vs history

Dividends

Assets vs Liabilities $m

Compound Annual Growth %

Earnings Trends EPS, adjusted, against the consensus

EPS $

Revenue $m

Operating Cash Flow $m

Free Cash Flow $m

Target Price Range

Recommendation Rating

Ten years at a glance Fiscal years to December

Actinium Pharmaceuticals, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Pay and ownership Proxy statement filed 15 October 2026

Chief executive’s pay

Ownership

Actinium Pharmaceuticals, Inc. (ATNM) Latest News

23 Oct

20 Oct

19 Oct

16 Oct

15 Oct

15 Sep

14 Aug

3 Jun

1 Jun

29 May

6 May

22 Apr

6 Apr

22 Dec

12 Dec

1 Dec

14 Nov

4 Nov

3 Nov

27 Oct

24 Oct

13 Oct

2 Sep

Stockrow Weekly